Takeda Reports Zasocitinib Achieves Rapid Skin Clearance
Takeda today announced Phase 3 results for zasocitinib (TAK-279), presented as a late-breaking abstract at the 2026 AAD Annual Meeting, showing rapid, durable skin clearance in adults with moderate-to-severe plaque psoriasis. About 70% of patients achieved clear or almost clear skin (sPGA 0/1) at week 16 versus 10–13% for placebo, with a safety profile consistent with Phase 2b findings.
Scoring Rationale
Phase 3, late-breaking AAD data provide high clinical credibility; limited impact for data-science-focused audiences.
Practice interview problems based on real data
1,500+ SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problemsStep-by-step roadmaps from zero to job-ready — curated courses, salary data, and the exact learning order that gets you hired.
Sources
- Read OriginalTakeda's Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Carefinancialpost.com
